M
MiNA Therapeutics
Biotech & Life Sciences · London, United Kingdom · Founded 2008
A platform that enables the development of new medicines that restore normal function to patients’ cells MoreLess
MiNA Therapeutics is a pioneering biotechnology company specializing in small activating RNA (RNAa) therapeutics. These innovative medicines harness the body's innate mechanisms to activate genes, thereby restoring or enhancing normal gene function and protein pathways in cells. MiNA's proprietary pipeline focuses on genetic medicine, aiming to address a broad spectrum of diseases. The company collaborates with leading pharmaceutical firms to expand the application of its technology across various therapeutic areas. MiNA operates in the biotechnology and pharmaceutical markets, targeting both rare and common diseases. Its business model involves developing and advancing RNAa-based therapies through clinical trials, often in partnership with other industry leaders. Revenue is generated through strategic collaborations, research partnerships, and potential future sales of approved therapies.
Keywords: RNAa therapeutics, gene activation, genetic medicine, biotechnology, pharmaceutical, clinical trials, rare diseases, strategic collaborations, protein pathways, innovative medicines.
Company overview
MiNA Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2008
- Headquarters
- London, United Kingdom
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 64.6
Valuation & funding
MiNA Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jul 2022 | $185K | — | Undisclosed | — |
| LATE VCOther financing | Jul 2021 | $14M | $152M | Eli Lilly | — |
| SERIES AOther financing | Sep 2020 | $30M | $121M | aMoon Fund | — |
| EARLY VCOther financing | May 2013 | $46M | $185M | Nxera Pharma | — |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $22M | 0% | 27 |
| 2025 | $22M | 0% | 28 |
| 2024 | $22M | 0% | 34 |
| 2023 | $22M | 0% | 37 |
| 2022 | $22M | 0% | 45 |
| 2021 | $22M | +839.4% | 30 |
| 2020 | $2.4M | — | — |
Growth signals
MiNA Therapeutics website traffic
Latest recorded traffic for MiNA Therapeutics is 1.1K monthly website visits, down 50% over the last three months. MiNA Therapeutics's team declined 3.6% over the past year.
Comparisons
MiNA Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
MiNA Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
3 investors on MiNA Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where MiNA Therapeutics has talent and traffic
team presence
In the news
Latest news about MiNA Therapeutics
Recent press, funding announcements, and product moves mentioning MiNA Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about MiNA Therapeutics
An AI-synthesized read of the highest-engagement posts about MiNA Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MiNA Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.